COVID-19 vaccine: Bharat Biotech fast-tracks Covaxin's trials, halves Phase 2 test sizeAs part of its effort to fast-track COVID-19 vaccine development, Hyderabad-based Bharat Biotech has cut the size of Phase 2 clinical trials of its indigenous coronavirus vaccine Covaxin by half. The vaccine, which Bharat Biotech is developing in collaboration with the country's apex medical research body - Indian Council of Medical Research (ICMR), will now be tested on 380 healthy volunteers in phase 2 a...

Coronavirus vaccine update: Bharat Biotech is ready to start Covaxin's Phase 3 trail to test the vaccine on about 28,500 volunteers

Coronavirus vaccine update: Biopharma company Epygen Biotech with operations in Mumbai and Dubai is planning to launch an affordable COVID-19 vaccine with an aim to roll out 500 million doses within six months

\"We're expecting that early next year we should have vaccine in the country from maybe more than one source,\" says union health minister Harsh Vardhan

Coronavirus vaccine: There are four US-based companies whose vaccine candidates have moved into the crucial phase-3 development phase. This includes--Pfizer, Moderna, Johnson & Johnson, and Novavax

According to sources, the phase-2 trial of the Covaxin is going on and the second dose is yet to be given to volunteers at some sites

Bharat Biotech vaccine: The subject expert committee that discussed the matter in a meeting on October 5 has asked the company to resubmit the protocol and clarify the definition of asymptomatic

COVID-19 vaccine: A principal investigator from a trial site in Maharashtra said that they are expecting to finish enrolling the participants within the next two months after which they will be monitored for the vaccine's efficacy

Coronavirus cases in India: The active patients' tally in India stands at 9,42,217; around 53,52,078 patients have recovered and 99,773 have succumbed to the deadly virus so far

Coronavirus vaccine update: In India, there are three COVID-19 vaccines under human trials--Bharat Biotech's COVAXIN, Oxford's COVDSHIELD, and Zydus Cadila's ZyCoV-D. Serum Institute has already begun a phase-3 trial of Oxford vaccine candidates at 17 sites

COVID-19 vaccine being developed by AstraZeneca-Oxford University, Novavax, Moderna, Pfizer Inc and Johnson & Johnson are already in an advanced stage of testing

Coronavirus vaccine trials: While China has four vaccine candidates in third or final stages of clinical trials, there are at least two companies from the United States and one from UK and Germany, which are planning to rollout vaccine before December, if everything goes as per the plan

COVID-19 vaccine candidates being developed by Cadila Healthcare and Bharat Biotech have completed the phase one of the study while Pune-based Serum Institute of India (SII) will begin with Phase 3 clinical trial after getting regulatory nod, says ICMR chief

Pfizer says trial is event-based and there are many variables that will ultimately impact read-out timing; adds if trials are successful, these companies would submit vaccines for approval as early as October

The committee \"has concluded its investigations and recommended to the MHRA that trials in the UK are safe to resume\", AstraZeneca' said

Bharat Biotech says its vaccine candidate was found to generate \"robust immune responses\", thus preventing infection and disease in primates upon high amounts of exposure to live SARS-CoV-2 virus

Another leading candidate for coronavirus vaccine is Moderna. The company said that it is talking to multiple countries for the rollout of the COVID-19 vaccine.

AstraZeneca CEO Pascal Soriot said that the decision to resume the coronavirus vaccine trials rests with a group of independent experts who are working to understand if the volunteer's condition was coincidental or a result of the inoculation

Phase 2/3 COVID-19 vaccine trials being conducted across 17 sites in India paused till further instructions from regulator; could delay vaccine development process as Serum Institute is front-runner when it comes to companies producing COVID-19 vaccines in India

Serum has also started manufacturing the vaccine, targeting to use in India and 92 other countries upon completion of trials and regulatory clearances